New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia

Since the introduction of new anthracycline derivatives and anthrachi­ none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig­ nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacin